Invivyd (IVVD) vs. The Competition Head to Head Analysis

Invivyd (NASDAQ:IVVD) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Invivyd to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Invivyd and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1	1	3	0	2.40
Invivyd Competitors	9903	15310	45655	1602	2.54

Invivyd presently has a consensus price target of $10.00, indicating a potential upside of 1,617.92%. As a group, “Biotechnology” companies have a potential upside of 126.19%. Given Invivyd’s higher probable upside, equities analysts plainly believe Invivyd is more favorable than its rivals.

Valuation & Earnings

This table compares Invivyd and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Invivyd	$53.43 million	-$52.49 million	-1.76
Invivyd Competitors	$719.47 million	$11.20 million	-18.80

Invivyd’s rivals have higher revenue and earnings than Invivyd. Invivyd is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Invivyd has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Invivyd’s rivals have a beta of -1.88, suggesting that their average stock price is 288% less volatile than the S&P 500.

Insider & Institutional Ownership

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 12.2% of Invivyd shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Invivyd and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Invivyd Competitors	-12,319.70%	-407.93%	-30.95%

Summary

Invivyd rivals beat Invivyd on 7 of the 13 factors compared.

About Invivyd

Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.